Overview

Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Status:
Completed
Trial end date:
2000-03-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and surgery in treating patients who have newly diagnosed metastatic osteosarcoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Calcium
Doxorubicin
Ifosfamide
Leucovorin
Levoleucovorin
Liposomal doxorubicin
Methotrexate
Trimetrexate
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed, newly diagnosed (within one month of
biopsy) malignant high grade osteosarcoma Must have pulmonary metastases (two or more
nodules) and/or disease involving other bones or organs Must be an intent to resect at
least one primary and/or metastatic site following preoperative chemotherapy Must have at
least 1 evaluable site of disease No radiation induced sarcoma No osteosarcoma arising in
premalignant bony lesions (e.g. Paget's disease)

PATIENT CHARACTERISTICS: Age: 30 and under Performance status: Not specified Life
expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 3.0
times normal SGOT and/or SGPT less than 3.0 times normal Renal: Creatinine no greater than
1.5 times normal OR Creatinine clearance or radioisotope GFR greater than 70 mL/min
Cardiovascular: Shortening fraction greater than 28% by echocardiogram OR Ejection fraction
greater than 50% by radionuclide angiogram No history of pericarditis or myocarditis

PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunomodulating agents except
steroids Chemotherapy: No prior chemotherapy No other concurrent chemotherapy Endocrine
therapy: No concurrent immunomodulating agents except steroids Radiotherapy: No prior or
concurrent radiotherapy Surgery: Prior biopsy only of primary or metastatic area No prior
resection Other: No prior therapy for any other malignancy No concurrent co-trimoxazole